164 related articles for article (PubMed ID: 31769861)
1. CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLL.
Fakhri B; Andreadis C
Oncology (Williston Park); 2019 Nov; 33(11):. PubMed ID: 31769861
[No Abstract] [Full Text] [Related]
2. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Al-Sawaf O; Zhang C; Tandon M; Sinha A; Fink AM; Robrecht S; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Tausch E; Schary W; Ritgen M; Wendtner CM; Kreuzer KA; Eichhorst B; Stilgenbauer S; Hallek M; Fischer K
Lancet Oncol; 2020 Sep; 21(9):1188-1200. PubMed ID: 32888452
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax Data Prompt Rethink of CLL Therapy.
Cancer Discov; 2018 Mar; 8(3):OF5. PubMed ID: 29382644
[TBL] [Abstract][Full Text] [Related]
4. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Fischer K; Al-Sawaf O; Bahlo J; Fink AM; Tandon M; Dixon M; Robrecht S; Warburton S; Humphrey K; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Boettcher S; Tausch E; Humerickhouse R; Eichhorst B; Wendtner CM; Langerak AW; Kreuzer KA; Ritgen M; Goede V; Stilgenbauer S; Mobasher M; Hallek M
N Engl J Med; 2019 Jun; 380(23):2225-2236. PubMed ID: 31166681
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 among fit patients with CLL treated with venetoclax-based combinations.
Fürstenau M; Langerbeins P; De Silva N; Fink AM; Robrecht S; von Tresckow J; Simon F; Hohloch K; Droogendijk J; van der Klift M; van der Spek E; Illmer T; Schöttker B; Fischer K; Wendtner CM; Tausch E; Stilgenbauer S; Niemann CU; Gregor M; Kater AP; Hallek M; Eichhorst B
Leukemia; 2020 Aug; 34(8):2225-2229. PubMed ID: 32601378
[No Abstract] [Full Text] [Related]
6. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Tausch E; Schneider C; Robrecht S; Zhang C; Dolnik A; Bloehdorn J; Bahlo J; Al-Sawaf O; Ritgen M; Fink AM; Eichhorst B; Kreuzer KA; Tandon M; Humphrey K; Jiang Y; Schary W; Bullinger L; Mertens D; Lurà MP; Kneba M; Döhner H; Fischer K; Hallek M; Stilgenbauer S
Blood; 2020 Jun; 135(26):2402-2412. PubMed ID: 32206772
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Fischer K; Al-Sawaf O; Fink AM; Dixon M; Bahlo J; Warburton S; Kipps TJ; Weinkove R; Robinson S; Seiler T; Opat S; Owen C; López J; Humphrey K; Humerickhouse R; Tausch E; Frenzel L; Eichhorst B; Wendtner CM; Stilgenbauer S; Langerak AW; van Dongen JJM; Böttcher S; Ritgen M; Goede V; Mobasher M; Hallek M
Blood; 2017 May; 129(19):2702-2705. PubMed ID: 28325865
[No Abstract] [Full Text] [Related]
8. Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.
Innocenti I; Morelli F; Autore F; Piciocchi A; Frustaci A; Mauro FR; Schiattone L; Trentin L; Del Poeta G; Reda G; Rigolin GM; Ibatici A; Ciolli S; Coscia M; Sportoletti P; Murru R; Levato L; Gentile M; D'Arena G; Efremov DG; Tedeschi A; Scarfò L; Cuneo A; Foà R; Laurenti L
Br J Haematol; 2019 Oct; 187(1):e8-e11. PubMed ID: 31364153
[No Abstract] [Full Text] [Related]
9. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.
Hampel PJ; Call TG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Rabe KG; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
Am J Hematol; 2020 Mar; 95(3):E57-E60. PubMed ID: 31788844
[No Abstract] [Full Text] [Related]
10. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
[TBL] [Abstract][Full Text] [Related]
11. High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia.
Al-Sawaf O; Lilienweiss E; Bahlo J; Robrecht S; Fink AM; Patz M; Tandon M; Jiang Y; Schary W; Ritgen M; Tausch E; Stilgenbauer S; Eichhorst B; Fischer K; Hallek M; Kreuzer KA
Blood; 2020 Mar; 135(11):866-870. PubMed ID: 31990291
[No Abstract] [Full Text] [Related]
12. Ibrutinib: searching for a partner drug.
Kater AP; Brown JR
Lancet Oncol; 2019 Jan; 20(1):3-5. PubMed ID: 30522966
[No Abstract] [Full Text] [Related]
13. Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia.
Blair HA
Drugs; 2020 Dec; 80(18):1973-1980. PubMed ID: 33201424
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
Al-Sawaf O; Gentile B; Devine J; Zhang C; Sail K; Tandon M; Fink AM; Kutsch N; Wendtner CM; Eichhorst B; Hallek M; Fischer K
Am J Hematol; 2021 Sep; 96(9):1112-1119. PubMed ID: 34050972
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.
Rogers KA; Huang Y; Ruppert AS; Abruzzo LV; Andersen BL; Awan FT; Bhat SA; Dean A; Lucas M; Banks C; Grantier C; Heerema NA; Lozanski G; Maddocks KJ; Valentine TR; Weiss DM; Jones JA; Woyach JA; Byrd JC
J Clin Oncol; 2020 Nov; 38(31):3626-3637. PubMed ID: 32795224
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia.
Stephens DM
Blood; 2019 Nov; 134(20):1691-1696. PubMed ID: 31488409
[TBL] [Abstract][Full Text] [Related]
17. Pairing obinutuzumab with venetoclax in relapsed CLL.
Rogers KA; Thompson PA
Leuk Lymphoma; 2024 May; 65(5):543-545. PubMed ID: 38497550
[No Abstract] [Full Text] [Related]
18. Alliance to iLLUMINATE the chemo-free sign.
Romero D
Nat Rev Clin Oncol; 2019 Feb; 16(2):65. PubMed ID: 30575810
[No Abstract] [Full Text] [Related]
19. Appendix 4: Chronic lymphocytic leukaemia: eUpdate published online 27 June 2017 (www.esmo.org/Guidelines/Haematological-Malignancies).
ESMO Guidelines Committee
Ann Oncol; 2017 Jul; 28(suppl_4):iv149-iv152. PubMed ID: 28881925
[No Abstract] [Full Text] [Related]
20. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
Cramer P; von Tresckow J; Bahlo J; Robrecht S; Langerbeins P; Al-Sawaf O; Engelke A; Fink AM; Fischer K; Tausch E; Seiler T; Fischer von Weikersthal L; Hebart H; Kreuzer KA; Böttcher S; Ritgen M; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M
Lancet Oncol; 2018 Sep; 19(9):1215-1228. PubMed ID: 30115596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
